Edgewise Therapeutics, Inc. (EWTX) SEC Filings & Earnings Calls

Net loss increased to $57.3M from $36.1M due to higher R&D and G&A expenses.

“Net loss $57.3M vs $36.1M prior year”

Transition to cardiovascular-focused company introduces execution risk for pipeline.

“Company transitioning to cardiovascular-focused company after selling muscular dystrophy business.”

Dependence on future capital raises

“The Company’s ability to fund ongoing operations is highly dependent upon raising additional capital through the issuance of equity securities and issuing debt or other financing vehicles.” · word for word

Significant operating losses expected to continue

“we expect to continue to incur significant losses for the foreseeable future as we advance our product candidates through preclinical development and clinical trials and seek regulatory approval of our product candidates.” · word for word

Clinical and regulatory risk for pipeline candidates

“Our lead cardiovascular program, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multipart Phase 2 trial... EDG-15400... currently in a Phase 1 trial... we expect to initiate a Phase 2 trial in the second half of 2026.” · word for word

Execution risk in transitioning to cardiovascular-focused pipeline; reliance on EDG-7500 success.

“Company now depends on cardiovascular pipeline success after divesting muscular dystrophy program.”

Milestone payments are contingent on regulatory and commercial achievements, not guaranteed.

“up to $1.1 billion in additional milestone payments” · word for word

Transaction subject to antitrust and other closing conditions; may not close.

“The consummation of the Transaction is subject to the satisfaction of customary closing conditions, including the termination or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.” · word for word

Pre-revenue biotech with no approved products

“To date, we have financed our operations primarily through private placements of convertible preferred stock and public offerings of our common stock.” · word for word

Dependence on clinical trial success

“The successful development of our product candidates is highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing and extent of expenses necessary to complete the development of our product candidates.” · word for word

Need for additional capital

“The Company’s ability to fund ongoing operations is highly dependent upon raising additional capital through the issuance of equity securities and issuing debt or other financing vehicles.” · word for word

Clinical trial risk: GRAND CANYON pivotal data in Q4 2026; failure would impair Becker MD program.

“Expects to report top-line data in the fourth quarter of 2026.” · word for word

Pre-revenue stage: no approved products; cash burn not disclosed in excerpt.

“No revenue or cash position disclosed.”

Dilution from equity issuance

“This Amendment No. 6 is being filed to report the dilution of the Reporting Person's beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Person.” · word for word

Dilution from equity issuance

“This Amendment No. 6 is being filed to report the dilution of the Reporting Person's beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Person.” · word for word

Clinical trial failure risk

“The FDA labels for all four drugs state that a clinical benefit has not yet been established and that continued approval may be contingent upon the verification of such clinical benefit in confirmatory clinical trials.” · word for word

Competitive pressure from gene therapy

“In June 2023, the FDA approved Sarepta’s Biologics License Application seeking accelerated approval of their microdystrophin gene therapy, Elevidys.” · word for word

Clinical trial risk; no approved products; reliance on pipeline success.

“No revenue from approved products; pipeline stage.”

Leadership transition risk.

“CFO retirement and replacement.”

Clinical trial risk: GRAND CANYON readout in Q4 2026; potential for failure

“Pivotal GRAND CANYON cohort... expected to read out in Q4 2026”

Dependence on pipeline success; no approved products yet

“All programs are in clinical development; no commercial revenue.”

Clinical-stage biotech with no approved products

“We have incurred significant losses since the commencement of our operations.” · word for word

Increasing operating losses

“Net loss (40,666) (34,129) (117,579) (94,151)” · word for word

Dependence on future capital raises

“The Company’s ability to fund ongoing operations is highly dependent upon raising additional capital” · word for word